Development of the ADHD Treatment Satisfaction Questionnaire (ATSQ) for Use with Children, Adolescents, and Their Caregivers

Andrew Palsgrove,¹ Mark J. Atkinson,^{2,3} Jason C. Cole,⁴ Caroline L. Ward,¹ Jeff Schein,¹ Dorothee Oberdhan¹

¹Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD, USA; ²COA Evidentiary Analytics, LLC, Powers, OR, USA; ³Department of Family Medicine and Public Health, University of California San Diego, San Diego, CA, USA; ⁴P3 Research Consulting, Inc., Torrance, CA, USA.

Introduction

- A substantial proportion of patients diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD) receive treatment, yet nearly half of them switch or discontinue their treatment regimen within 12 months.^{1,2}
- Currently available ADHD treatments may be associated with burdensome side effects, risk for abuse, and/or lack of efficacy in some patients.^{3,4}
- The ADHD Treatment Satisfaction Questionnaire (ATSQ) was developed to investigate treatment satisfaction, treatment preference, and reasons for prior treatment changes in clinical trials with pediatric ADHD patients.⁵
- Questionnaire versions were developed appropriate to different age ranges used in the clinical trial program (children, 4-12 years via caregiver report; adolescents, 13-17 years via caregiver and self-report).⁵
- We previously evaluated the psychometric properties of two ATSQ versions designed to assess adolescents, either by self-report (ATSQ-A) or by caregiver report (ATSQ-PA).⁵
- The current study validates the conceptual framework and reliability of an ATSQ version for caregivers of children with ADHD (ATSQ-PC).

Methods


Questionnaire Content


- The ATSQ was developed based on a review of relevant literature and internal stakeholder input.
- Cognitive interviews were conducted in parent/ caregiver dyads to evaluate the recall period, survey questionnaire instructions, items on the survey questionnaire, and response options.

Study Analyses

- The conceptual framework was assessed using confirmatory factor analysis.
- Previously, data from an Otsuka clinical trial in adolescents with ADHD (NCT05257265) were used to examine latent models from the ATSQ-A and ATSQ-PA versions of the treatment satisfaction questionnaire, confirming their structural validity.⁵
- In the present assessment of the ATSQ-PC, data from an Otsuka clinical trial in children with ADHD (NCT05428033) were randomly split into two samples to allow for model refinement in one exploratory sample (n=147) and a confirmation sample (n=220).
- Classical psychometric reliability statistics were evaluated

Results







We found strong support linking qualitative research, theoretical underpinnings of ADHD-specific treatment satisfaction, and the quantitative support of the conceptual framework. Values for comparative fit index and root mean square error of approximation were well within acceptable limits (Table 1).6-8

*Fifty-two cases were removed per listwise deletion based on all variables in the procedure.

Content Development

• Literature review of ADHD medication preference and satisfaction research

• Existing treatment satisfaction questionnaires reviewed for methodology and item structure Cognitive interviews with 3 dyads of caregivers and adolescents

 Item concepts, stems, and response options were found to be clear, relevant, and easy to answer by caregivers and adolescents. No edits were required.

Questionnaire Concepts

Positive attributes of study medication

- Negative attributes of study medication
- Overall satisfaction of study medication
- Impacts on child's life (activities of daily living)
- Reasons for discontinuation
- Comparison with prior medications
- Duration of the study medication effect
- Side effects
- Out-of-pocket costs

ATSQ Structural Evaluation

ATSQ-A & ATSQ-PA

Source data: Trial NCT05257265

Sample: 279 adolescents, 257 caregivers for adolescents

ATSQ-PC

Source data: Trial NCT05428033

Sample: 315 caregivers for children*

The questionnaires demonstrated structural fidelity between the conceptual model and the confirmatory factor analysis for two summary scores:

Daily Impact

Comparison Rating

Cronbach's alpha and Spearman-Brown adjusted alpha values were high for both Daily Impact and the Comparison Rating, indicating the high internal consistency of each domain (Table 2).

Item-level statistics, including mean and standard deviation, the range of inter-item correlations, and item-total correlations were acceptable for both domains (data not shown).

Items and latent factors (concepts) were identical for ATSQ-A and ATSQ-PA. For the ATSQ-PC, one additional item ("completing work at home") was included in the Daily Impact factor. Otherwise, the overall structure remained consistent with the ATSQ-A and ATSQ-PA (Figure).

le 1. Model/Sample	CFI	RMSEA (90% CI)	Table 2.		ATSQ-A		ATSQ-PA		ATSQ-PC		
stics ATSQ-A	0.960	0.085 (0.057 - 0.114)	Internal Consistency		Daily Impact	Comparison Rating	Daily Impact	Comparison Rating	Daily Impact	Comparison Rating	
ATSQ-PA	0.967	0.095 (0.068 - 0.123)		Number of items	7	3	7	3	8	3	
ATSQ-PC	0.991	0.051 (0.022 - 0.075)		Cronbach's alpha Spoarman-Brown	0.882	0.849	0.927	0.918	0.955	0.903	
ative fit index; CI, confidence interval; RMSE	A, root mean square er	ror of approximation.		Spearman-Brown adjusted alpha	0.914	0.949	0.948	0.974	0.964	0.969	
re. Structure of th	e ATSQ										
TSQ-A & ATSQ-PA ⁵		Δ 5		ATSQ-PC		C	onclu	sions			
						Ev	aluation	n of factors	related	to	
Overall abor	acin			Overallebonge	n			satisfactio			
Overall chan ADHD symp	•				Verall change in HD symptoms (2A)		patients' experience from the clinical				
						tria	als and	their exper	ience w	ith the	
				Cotting along							
Getting along wi	th family		1	Getting along with family (2B)		udy med	lication.			
Getting along wi				with family (2B		stı					
						stu Co	ombinec	l with previ	ous res	ults of	
Ability to make ne	ew friend	S		with family (2B Ability to make new friends (2D)	Stu Co the	ombinec e ATSQ-		ous res SQ-PA v	ults of ersions,	
Ability to make ne	ew friend	S		with family (2B Ability to make)	stu Co the thi su	ombined e ATSQ- s new a pport fo	l with previ A and ATS nalysis pro	ous res Q-PA v ovides s	ults of ersions, trong	
Ability to make ne	ew friend	S		with family (2B Ability to make new friends (2D Completing wor at school (2F)) K	stu Co the thi su	ombinec e ATSQ- s new a	l with previ A and ATS nalysis pro	ous res Q-PA v ovides s	ults of ersions, trong	
Getting along wi Ability to make ne Completing work	ew friend	S		with family (2B Ability to make new friends (2D Completing wor) K	stu Co the thi su AT	ombined e ATSQ- s new a pport fo SQ-PC	l with previ A and ATS nalysis pro r using two	ous res Q-PA v ovides s o domai	ults of ersions, trong ns in the	
Ability to make ne	ew friend at schoc	s D Daily		with family (2B Ability to make new friends (2C Completing wor at school (2F) Completing wor at home (2E)*	k k	Stu Co the thi su AT	ombined e ATSQ- s new a pport fo SQ-PC	I with previ A and ATS nalysis pro r using two	ous res Q-PA v ovides s o domai	ults of ersions, trong ns in the erpreting	
bility to make ne	ew friend at schoc	s D Daily		with family (2B Ability to make new friends (2D Completing wor at school (2F)	k k	stu Co the thi su AT Fa the	ombined e ATSQ- s new a pport fo SQ-PC	l with previ A and ATS nalysis pro r using two	ous res Q-PA v ovides s o domai	ults of ersions, trong ns in the erpreting cross the	

Ability to learn

Feeling anxious or worried

Medication worked better

Medication lasted longer

Preferred medication

ADHD, Attention-Deficit/Hyperactivity Disorder.

Feeling anxious or worried (2K)

Ability to learn (2J)

Medication worked better (7A)

Medication lasted longer (7B)

Comparison >

rating

Preferred medication (7E)

*The addition of this item is the only structural difference from the ATSQ-PA and ATSQ-A.

Poster presented at the ISPOR 2024 Annual Meeting May 5–8, 2024; Atlanta, Georgia

patient-reported domains.

References

- 1. Polanczyk GV et al. Int J Epidemiol. 2014;43:434-42.
- 2. Schein J et al. Curr Med Res Opin. 2021;37:2007-14.
- 3. Schein J et al. Adv Ther. 2022;39:5487-503. 4. Katzman MA et al. BMC Psychiatry. 2017;17:302.
- 5. Palsgrove et al. Poster presented at International Society for Quality of Life Research (ISOQOL) Conference, October 18-23, 2023; Calgary, Alberta, Canada, Poster 1038.
- 6. Bentler PM. Psychol Bull. 1990;107:238-246.
- 7. Marsh HW et al. Struct Equat Model. 2004;11:320-341.
- 8. Steiger JH et al. Statistically-based Models Tests for the Number of Common Factors. 1980. Paper presented at the Psychometric Society Meeting, Iowa City, IA.

Disclosures

AP, CLW, JS, and **DO** are full-time employees of Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD, USA. MJA reports employment with COA Evidentiary Analytics, LLC, Powers, OR, USA, which was contracted with Otsuka to perform study analyses. JCC is the sole owner of P3 Research Consulting, Inc., Torrance, CA, USA, which was contracted with Otsuka to perform study analyses.

Acknowledgements

This work was supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (Rockville, MD, USA). The sponsors thank the patients and their families who participated in these studies.